In Regeneron Pharmaceuticals v. Formycon, Arun Sharma testified on behalf of defendant Formycon regarding irreparable harm and other injunction factors in connection with Regeneron's motion for a preliminary injunction to block a biosimilar version of Regeneron's Eylea®.
Partner with a firm that delivers rigorous economic research and practical advice.
By using this site, you agree to our updated Cookie Policy, Privacy Policy, and our Terms & Conditions.
When you visit our website, we use cookies on your browser to collect information. The information collected might relate to you, your preferences, or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. For more information about how we use cookies, please see our Cookie Policy and Privacy Policy.
